🇺🇸 FDA
Pipeline program

Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT

XMYY-2025KY280

Unknown other active

Quick answer

Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT for DLL3-expressing Tumors is a Unknown program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
DLL3-expressing Tumors
Phase
Unknown
Modality
other
Status
active

Clinical trials